TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Reports from University of Paris describe recent advances in tuberculosis
February 17th, 2009
"R207910 (TMC207 or J) is a member of the diarylquinolines, a new family of antituberculous drugs with high bactericidal activity when given daily in the murine model of tuberculosis. R207910 exhibits a long half-life and thus is a good candidate for once-weekly therapy of tuberculosis," scientists in Paris, France report. "To study the activity of once-weekly R207910 monotherapy and combinations of R207910 with other antituberculous agents (isoniazid, rifapentine, moxifloxacin, and pyrazinamide). The established infection model of murine tuberculosis was used. Colony counts were determined in the lungs. Eight weeks of monotherapy reduced the bacillary load by 3 to 4...
Source: TB & Outbreaks Week (2009-02-17)
|
